| Date | Time | Source | |
| 05/14/2013 | 4:30PM | PRNUS | Lilly Oncology to Release New Pipeline Data at ASCO 2013
Lilly Oncology to Release New Pipeline Data at ASCO 2013 Data from Pipeline Molecules Targeting Key Cancer Pathways to be Presented PR Newswire INDIANAPOLIS, May 14, 2013 INDIANAPOLIS, May 14, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from key molecules that make up its clinical oncology... More...>> |
| 05/14/2013 | 12:50PM | ZACKS | Amgen to Set Up JV in China - Analyst Blog
Amgen (AMGN) recently announced its intention to set up a joint venture (JV) in China with Zhejiang Beta Pharma Co., Ltd. The JV will focus on the commercialization of Amgen’s colorectal cancer drug, Vectibix, in China. While Zhejiang Beta Pharma will hold a 51% stake in the JV, Amgen-Beta Pharmaceuticals Co... More...>> |
| 05/14/2013 | 9:44AM | DJN | Lilly CEO Recovering From Surgery for Dilated Aorta
By Saabira Chaudhuri Eli Lilly & Co. (LLY) said Chairman and Chief Executive John C. Lechleiter is recovering from Monday surgery for a dilated aorta. "Dr. Lechleiter's surgeons have advised us that surgery went as expected and the repair to the aorta is functioning as intended," said Kristine A. Courtney, senior director... More...>> |
| 05/14/2013 | 9:00AM | PRNUS | Lilly Provides Update on CEO Dr. John Lechleiter
Lilly Provides Update on CEO Dr. John Lechleiter PR Newswire INDIANAPOLIS, May 14, 2013 INDIANAPOLIS, May 14, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that John C. Lechleiter, Ph.D., chairman, president, and chief executive officer, underwent scheduled surgery for a dilated aorta on Monday... More...>> |
| 05/13/2013 | 7:30AM | ZACKS | Lilly Scraps Oncology Candidate - Analyst Blog
Eli Lilly and Company (LLY) recently announced a pipeline setback with its oncology candidate, enzastaurin, failing in a phase III study. Eli Lilly was evaluating enzastaurin as a monotherapy for the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL). Results from the phase III PRELUDE study showed... More...>> |
| 05/10/2013 | 9:13AM | DJN | Eli Lilly Ends Development of Lymphoma Drug Enzastaurin; Missed Study Endpoint
By Melodie Warner Eli Lilly & Co. (LLY) said it will stop developing enzastaurin because a late-stage study showed the drug didn't significantly increase the survival of patients with diffuse large B-cell lymphoma. The pharmaceutical company backed its full-year guidance, but said it will book a roughly $30 million... More...>> |
| 05/10/2013 | 8:00AM | PRNUS | Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma PR Newswire INDIANAPOLIS, May 10, 2013 INDIANAPOLIS, May 10, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today Phase III clinical trial results from enzastaurin's PRELUDE study, which explored... More...>> |
| 05/06/2013 | 6:58PM | DJN | 2nd UPDATE: Lilly CEO to Have Artery Surgery, Seen Returning by Fall
--CEO Lechleiter to undergo surgical repair of enlarged aorta on May 13 --Lilly CFO Rice to become acting CEO during surgery and recovery period --Lead director Marram to become acting chairperson of board (Adds further detail about acting CEO in 7th paragraph) By Peter Loftus Drug maker Eli Lilly & Co. (LLY) said... More...>> |
| 05/06/2013 | 6:40PM | DJN | Lilly CEO to Have Artery Surgery, Seen Returning By Fall
--CEO Lechleiter to undergo surgical repair of enlarged aorta on May 13 --Lilly CFO Rice to become acting CEO during surgery and recovery period --Lead director Marram to become acting chairperson of board Drug maker Eli Lilly & Co. (LLY) said Chairman and Chief Executive John C. Lechleiter will hand over his duties... More...>> |
| 05/06/2013 | 6:38PM | PRNUS | Retrospective analysis of linagliptin data in sub-populations with type 2 diabetes presented at AACE 22nd Annual Scientific &...
Retrospective analysis of linagliptin data in sub-populations with type 2 diabetes presented at AACE 22nd Annual Scientific & Clinical Congress Retrospective pooled analyses evaluated linagliptin treatment in American Hispanic/Latino people with type 2 diabetes, as well as in people living with type 2 diabetes for... More...>> |
| 05/06/2013 | 6:18PM | DJN | UPDATE: Lilly CEO To Have Artery Surgery, Seen Returning By Fall
--CEO Lechleiter to undergo surgical repair of enlarged aorta on May 13 --Lilly CFO Rice to become acting CEO during surgery and recovery period --Lead director Marram to become acting chairperson of board (Adds details about surgery beginning in 2nd paragraph.) By Peter Loftus Drug maker Eli Lilly & Co. (LLY) said... More...>> |
| 05/06/2013 | 5:20PM | DJN | Eli Lilly CEO to Undergo Surgery Next Week; Expected to Return to Duties Later This Summer
By Tess Stynes Eli Lilly & Co. (LLY) Chairman and Chief Executive John C. Lechleiter is scheduled to undergo surgery next week for a dilated aorta and is expected to make a full recovery and return to his duties later this summer. The pharmaceutical giant said that Lilly Chief Financial Officer Derica W. Rice will... More...>> |
| 05/06/2013 | 4:30PM | PRNUS | Lilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery
Lilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery PR Newswire INDIANAPOLIS, May 6, 2013 INDIANAPOLIS, May 6, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that John C. Lechleiter, Ph.D., chairman, president, and chief executive officer, will undergo scheduled surgery for a dilated... More...>> |
| 05/06/2013 | 2:30PM | PRNUS | Lilly Declares Second-Quarter 2013 Dividend
Lilly Declares Second-Quarter 2013 Dividend PR Newswire INDIANAPOLIS, May 6, 2013 INDIANAPOLIS, May 6, 2013 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the second quarter of 2013 of $0.49 per share on outstanding common stock. The dividend is payable June 10... More...>> |
| 05/02/2013 | 8:00AM | PRNUS | Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in ty...
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes The SGLT disease education campaign provides resources for healthcare professionals about the role of sodium glucose co-transporters in maintaining blood sugar balance PR Newswire RIDGEFIELD... More...>> |
| 05/01/2013 | 4:13PM | DJN | 3rd UPDATE: Merck 1st-Quarter Profit Down on Loss of Singulair Exclusivity
--Merck first-quarter sales disappoint, lowers 2013 outlook --Sales of diabetes drug Januvia post rare decline amid new competition --CEO says Merck will deploy more resources toward Januvia (Adds background about broader drug sector beginning in 1st paragraph; updates stock price.) By Peter Loftus Major drug makers are... More...>> |
| 05/01/2013 | 2:58PM | BW | The Importance of Emergency Preparedness: Lilly Diabetes & the American College of Endocrinology (ACE) Help Prep People with ...
News Highlights: ACE, Lilly Diabetes offer emergency tips for people w/ #diabetes at www.EmPowerYourHealth.org, tips now downloadable in Spanish Lilly Diabetes and ACE have distributed approximately 12 million #diabetes emergency prep checklists since ‘06 www.EmPowerYourHealth.org A hurricane warning. A lengthy power... More...>> |
| 05/01/2013 | 1:00PM | PRNUS | The Importance of Emergency Preparedness: Lilly Diabetes and the American College of Endocrinology (ACE) Help Prep People wit...
The Importance of Emergency Preparedness: Lilly Diabetes and the American College of Endocrinology (ACE) Help Prep People with Diabetes for Emergencies - Big or Small How-to video, English and Spanish checklists available to aid advance planning PR Newswire PHOENIX, May 1, 2013 PHOENIX, May 1, 2013 /PRNewswire/ -- News... More...>> |
| 05/01/2013 | 10:47AM | DJN | 2nd UPDATE: Merck 1st-Quarter Profit Down on Loss of Singulair Exclusivity
--Merck first-quarter sales disappoint, lowers 2013 outlook --Sales of diabetes drug Januvia post rare decline amid new competition --CEO says Merck will deploy more resources toward Januvia (Adds factors pressuring Merck sales and comments from new head of research and development beginning in 5th paragraph; updates stock... More...>> |
| 05/01/2013 | 5:36AM | ZACKS | Stocks Market News for May 1, 2013 - Market News
A strong rally in technology shares along with encouraging economic reports on the home front lifted major indices higher on Tuesday. Both the S&P 500 and the Nasdaq recorded their sixth consecutive month of gains. The Dow Jones finished in the green for the fifth month in a row. The Street also received a mixed bag... More...>> |
